Skip to content
Screener

Capricor Therapeutics CAPR Business Segments — Investment Income Interest And Dividend

Similar metrics at other companies

NL Industries logo
NLSingle Reportable — Investment Income Interest And Dividend
$1.14M-23.9%
Boston Omaha logo
BOCBOAM — Investment Income Interest And Dividend
$5K-37.5%
Boston Omaha logo
BOCBOB — Investment Income Interest And Dividend
$19K+5.6%
Boston Omaha logo
BOCGIG — Investment Income Interest And Dividend
$0
Boston Omaha logo
BOCLMH — Investment Income Interest And Dividend
$44K-6.4%
Great Elm Group, Inc. logo
GEGCredit — Investment Income Interest And Dividend
$0

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$242.07M-31.6%
Enterprise value$151.43M-54.3%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterestAndDividend.

The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060382
Total revenueThree months ended March 31, 2026 / —Three months ended March 31, 2025 / —
Depreciation and amortization253,355190,486
Total general and administrative expense9,395,9416,067,376
Operating loss(36,772,853)(24,982,948)
Investment income2,904,506729,542
Other income (expense)(72,998)(138,188)
Total non-operating income, net2,831,508591,354
Loss before income taxes(33,941,345)(24,391,594)
(Provision for) benefit from income taxes

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's business segments — investment income interest and dividend?
Capricor Therapeutics (CAPR) reported business segments — investment income interest and dividend of $2.9M in Q1 2026.
How has Capricor Therapeutics's business segments — investment income interest and dividend changed year-over-year?
Capricor Therapeutics's business segments — investment income interest and dividend increased by 298.1% year-over-year, from $729.54K to $2.9M.
What does business segments — investment income interest and dividend mean?
This represents the income earned from the company's cash reserves, marketable securities, or other financial investments. It serves as a source of non-operating revenue that helps offset the high costs of clinical development. Monitoring this provides insight into the company's treasury management and liquidity strategy.

Ask your AI about Capricor Therapeutics's business segments — investment income interest and dividend.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude